PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22139083-11	2012	Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio=3.18, confidence interval: 1.31-7.72, P=0.0106, n=291).	Platinum	105-113	KRAS proto-oncogene, GTPase	Homo sapiens	55-59	
22139083-13	2012	These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance.	Platinum	153-161	KRAS proto-oncogene, GTPase	Homo sapiens	88-92